"A Most Equitable Drug": How the Clinical Studies of Convalescent Plasma as a Treatment for SARS-CoV-2 Might Usefully Inform Post-Pandemic Public Sector Approaches to Drug Development

Quinn Grundy, Chantal Campbell, Ridwaanah Ali, Matthew Herder, and Kelly Holloway

Supplemental Files

Supplementary File 1

COREQ reporting guideline checklist. Consolidated criteria for reporting qualitative studies (COREQ): 32-item checklist

No. Item	Guide questions/description	Reported on Page #
Domain 1: Research team and reflexivity		
Personal Characteristics		
1. Interviewer/facilitator	Which author/s conducted the data abstraction?	Data collection and analysis; pg 8
2. Credentials	What were the researcher's credentials? E.g. PhD, MD	Title Page
3. Occupation	What was their occupation at the time of the study?	Title Page
4. Gender	Was the researcher male or female?	N/A
5. Experience and training	What experience or training did the researcher have?	Title Page
Relationship with participants		
6. Relationship established	Was a relationship established prior to study commencement?	N/A
7. Participant knowledge of the interviewer	What did the participants know about the researcher? e.g. personal goals, reasons for doing the research	N/A
8. Interviewer characteristics	What characteristics were reported about the inter viewer/ facilitator? e.g. Bias, assumptions, reasons and interests in the research topic	Introduction, Methods; Pages 4-7; Declarations
Domain 2: Study design		
Theoretical framework		
9. Methodological orientation and Theory	What methodological orientation was stated to underpin the study? e.g. grounded theory, discourse analysis, ethnography, phenomenology, content analysis	Introduction, Methods; Pages 3-7
Participant selection		
10. Sampling	How were participants selected? e.g. purposive, convenience, consecutive, snowball	Methods; Page 5-7
11. Method of approach	How were participants approached? e.g. face-to-face, telephone, mail, email	N/A
12. Sample size	How many participants were in the study?	Results; Pages 8-10; Supplementary File 3
13. Non-participation	How many people refused to participate or dropped out? Reasons?	N/A

The Journal of Law, Medicine & Ethics, 52 (2024): Online: 1-20. © The Author(s), 2024. Published by Cambridge University Press on behalf of American Society of Law, Medicine & Ethics. DOI: 10.1017/jme.2024.51

Supplementary File 1 (continued)

COREQ reporting guideline checklist. Consolidated criteria for reporting qualitative studies (COREQ): 32-item checklist

No. Item	Guide questions/description	Reported on Page #
Setting		
14. Setting of data collection	Where was the data collected? e.g. home, clinic, workplace	N/A
15. Presence of non-participants	Was anyone else present besides the participants and researchers?	N/A
16. Description of sample	What are the important characteristics of the sample? e.g. demographic data, date	Results; Page 8-10
Data collection		
17. Interview guide	Were questions, prompts, guides provided by the authors? Was it pilot tested?	Supplementary File 2
18. Repeat interviews	Were repeat interviews carried out? If yes, how many?	N/A
19. Audio/visual recording	Did the research use audio or visual recording to collect the data?	Methods; Page 6-7
20. Field notes	Were field notes made during and/or after the interview or focus group?	Methods; Page 6-7
21. Duration	What was the duration of the interviews or focus group?	N/A
22. Data saturation	Was data saturation discussed?	Methods; Page 6-7
23. Transcripts returned	Were transcripts returned to participants for comment and/or correction?	N/A
Domain 3: analysis and findings		
Data analysis		
24. Number of data coders	How many data coders coded the data?	Methods; Page 7
25. Description of the coding tree	Did authors provide a description of the coding tree?	Methods, Results; Page 7-15
26. Derivation of themes	Were themes identified in advance or derived from the data?	Methods, Results; Page 7, 11
27. Software	What software, if applicable, was used to manage the data?	Methods; Page 6-7
28. Participant checking	Did participants provide feedback on the findings?	N/A
Reporting		
29. Quotations presented	Were participant quotations presented to illustrate the themes/ findings? Was each quotation identified? e.g. participant number	Results; Page 11-24
30. Data and findings consistent	Was there consistency between the data presented and the findings?	Results; Page 11-24
31. Clarity of major themes	Were major themes clearly presented in the findings?	Results; Page 8-24
32. Clarity of minor themes	Is there a description of diverse cases or discussion of minor themes?	Results; Page 8-24

Developed from:
Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. International Journal for Quality in Health Care. 2007. Volume 19, Number 6: pp. 349 – 357

The Journal of Law, Medicine & Ethics, 52 (2024): Online: 1-20. © The Author(s), 2024. Published by Cambridge University Press on behalf of American Society of Law, Medicine & Ethics.

Supplementary File 2.

Data abstraction form

Study family ID:
Name of coder:
Date:

Highlights

Timeline

Key insights/questions/themes

Overview

1. Provide a brief overview of the study/trial including the country, key sites, key investigators, primary aim, and participant population. Note if the study is complete, underway, or stopped and any salient or distinctive features of the study design (e.g. RCT vs observational, controls etc.).
    - If a blood services operator is involved, please describe the nature of the involvement.
2. What kinds of documents are publicly available?
3. To what extent is the study public facing? For example, public websites, media coverage etc.

Identifying and describing the key entities and individuals involved

1. Where did the study source its convalescent plasma? To what extent is this entity involved in the study?
2. Who is the study funder and what is their involvement with the study? What is the nature of additional relationships between the sponsor and trialists or other entities?
3. How did the study identify and recruit study sites?
4. Are there any prominent individuals or campaigns that are promoting the study or encouraging plasma donation for the study?
   (I am mostly thinking celebrities, or campaigns like "The fight is in us," but I suppose this could include government too. Like I'm not sure if Trudeau has spoken publicly asking people to donate CP but that would count.)
5. Who is primarily responsible for the study/trial and integrity of the data? What is their role in the study?

Regulatory processes

1. Describe the existing regulatory oversight and context for convalescent plasma and relevant regulators for the study (i.e. emergency use authorization, off-label use authorization, trial-only status, research ethics boards, health product regulators, industry standards etc.).

Social aspects of clinical trial processes – facilitators and hurdles

1. What were key challenges or hurdles in conducting the trial?
2. What were key facilitators?
3. Other pragmatic issues?

Legal, ethical, and equity issues

1. Where did the entity source their convalescent plasma? Geographically? Population-wise?
2. How were convalescent plasma donors recruited? What information were they given about the study or the use of their plasma? What rights were they given in regard to withdrawal? Were they compensated and if so, how? What is the process for registration/donation? Were individual donors informed about their antibody levels (i.e. had results returned)?
3. How were study participants recruited? How is the convalescent plasma allocated or distributed (i.e. under emergency use or if proven safe and effective)?
4. What are the plans for sharing data about convalescent plasma recipients?
5. What intellectual property mechanisms pertain to the intervention (i.e. patent protection or other IP provision)?

The Journal of Law, Medicine & Ethics, 52 (2024): Online: 1-20. © The Author(s), 2024. Published by Cambridge University Press on behalf of American Society of Law, Medicine & Ethics.

Supplementary File 3

Catalogue of sampled documents.

Study Record ID	Document type	Document title	Document author	Document publisher	Date published	Date sampled
ChiCTR2000029757_ China	News	Everything you need to know about WeChat — China's billion-user messaging app	Kharpal, A	CNBC	03.02.2019	30.03.2021
ChiCTR2000029757_ China	News	Chinese man contributes 4,000mL of plasma to help COVID-19 patients	Kun, L & Nyima, P	China Daily	22.07.2020	21.03.2021
ChiCTR2000029757_ China	News	Effect of convalscent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19	Thompson, M	Twitter	10.06.2020	21.03.2021
ChiCTR2000029757_ China	News	Counseling plays a vital role	Jin Zhou and Kun Liu	China Daily	26.01.2021	24.03.2021
ChiCTR2000029757_ China	News	China Focus: China develops convalescent plasma therapy for COVID-19 patients	Huaxia	Xinhua Net	14.02.2020	31.03.2021
ChiCTR2000029757_ China	News	Convalescent plasma not helpful in China study; hydroxychloroquine doesn't prevent infection	Lapid, N	Reuters	03.06.2020	30.03.2021
ChiCTR2000029757_ China	News	Cured COVID-19 patients donate plasma to save more	Huaxia	Xinhua Net	18.02.2020	31.03.2021
ChiCTR2000029757_ China	News	Thankful COVID-19 patient gives plasma	Liu, K & Wang, X	China Daily	25.08.2020	31.03.2021
ChiCTR2000029757_ China	News	China's Wuhan to build COVID-19 convalescent plasma pool	Huaxia	Xinhua Net	07.07.2020	21.03.2021
ChiCTR2000029757_ China	Protocol	Convalescent plasma for the treatment of severe and critical/lifethreatening COVID-19: a prospective randomized controlled trial	Li et al.	JAMA	22.02.2020	20.03.2021
ChiCTR2000029757_ China	Publication	Feasibility of a pilot program for COVID-19 convalescent plasma collection in Wuhan, China	Ling Li et al.	Transfusion	31.07.2020	29.03.2021
ChiCTR2000029757_ China	Publication	Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19 A Randomized Clinical Trial	Li et al.	JAMA	03.06.2020	21.03.2021
ChiCTR2000029757_ China	Publication supplement	Data Sharing Statement	Li et al.	JAMA	01.06.2020	21.03.2021
ChiCTR2000029757_ China	Publication supplement	Supplementary Online Content	Li et al.	JAMA	04.08.2020	30.03.2021
ChiCTR2000029757_ China	Publication supplement	CCP workflow diagram - Feasibility of a pilot program for COVID-19 convalescent plasma collection in Wuhan, China	Ling Li et al.	Transfusion	31.07.2020	29.03.2021

The Journal of Law, Medicine & Ethics, 52 (2024): Online: 1-20. © The Author(s), 2024. Published by Cambridge University Press on behalf of American Society of Law, Medicine & Ethics.

Supplementary File 3 (Continued)

Catalogue of sampled documents.

Study Record ID	Document type	Document title	Document author	Document publisher	Date published	Date sampled
ChiCTR2000029757_China	Publication supplement	Recruitment material [chinese] (Feasibility of pilot program)	Ling Li et al.	Transfusion	31.07.2020	24.03.2021
ChiCTR2000029757_China	Publication supplement	Recruitment material - Supplemental material for figure 2 [English] (not a word-by-word translation) (Feasibility of pilot program)	Ling Li et al.	Transfusion	31.07.2020	24.03.2021
ChiCTR2000029757_China	Publication supplement	Statistiscal Analysis Plan	Li et al.	JAMA	03.06.2020	21.03.2021
ChiCTR2000029757_China	Regulatory	Position Paper on Use of Convalescent Plasma, Serum or Immune Globulin Concentrates as an Element in Response to an Emerging Virus	WHO Blood Regulators Network (BRN)	WHO	14.09.2017	21.03.2021
ChiCTR2000029757_China	Trial registry record	Convalescent plasma for the treatment of severe novel coronavirus pneumonia (COVID-19): a prospective randomized controlled trial (V1.1)	Zhong, L	Chinese Clinical Trial Registry	03.03.2020	21.03.2021
ChiCTR2000029757_China	Website	Trial ChiCTR2000029757	Covid-19 Living Data	Covid-19 Living Data	n.d.	21.03.2021
CONCOR_Canada	Conference presentation	CADTH Session on CONCOR	Canadian Agency for Drugs and Technologies	Canadian Agency for Drugs and Technologies	n.d.	25.08.2020
CONCOR_Canada	Conference presentation	CADTH session on Blood Plasma Therapies for COVID-19	Devine D, Callum J, McGurn S	Canadian Agency for Drugs and Technologies	n.d.	25.08.2020
CONCOR_Canada	News	Shrinking number of new COVID-19 patients in Canada slowing down major treatment study	Pinkerton, C	ipolitics.ca	22.05.2020	25.05.2020
CONCOR_Canada	News	Plasma project could use blood of COVID-19 survivors to help save the newly infected	Grant, K	The Globe and Mail	28.08.2020	28.08.2020
CONCOR_Canada	News	More hospitals part of plasma transfusion trial to treat COVID-19 with antibodies	Czlarski C, Canadian Press	CochraneTODAY	28.05.2020	29.03.2021
CONCOR_Canada	News	Convalescent Plasma Strikes Out as COVID-19 Treatment	Harris, R	KPBS	10.02.2020	29.03.2021
CONCOR_Canada	News	FDA under pressure from Trump, authorizes blood plasma as COVID-19 treatment	Florko, N	STAT	23.08.2020	31.08.2020
CONCOR_Canada	News	Major study finds convalescent plasma doesn't help seriously ill COVID-19 patients	McMaster University	McMaster University	9.10.2021	10.5.21

The Journal of Law, Medicine & Ethics, 52 (2024): Online: 1-20. © The Author(s), 2024. Published by Cambridge University Press on behalf of American Society of Law, Medicine & Ethics.

Supplementary File 3 (Continued)

Catalogue of sampled documents.

Study Record ID	Document type	Document title	Document author	Document publisher	Date published	Date sampled
CONCOR_Canada	Publication	Convalescent Plasma Therapy for the Treatment of COVID-19: A Review of Clinical Effectiveness	Subramonian A, Young C, Loshak H, McCormack S, Clark M	Canadian Agency for Drugs and Technologies	23.07.2020	10.12.2020
CONCOR_Canada	Publication	Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial	Begin, P et al	Nature Medicine	09.09.2021	10.5.21
CONCOR_Canada	Publication supplement	Steering Committee	CONCOR-1	CONCOR-1	n.d.	25.05.2020
CONCOR_Canada	Social media	100 patients enrolled in last 15 days…	CONCOR-1	CONCOR-1	26.10.2020	27.10.20
CONCOR_Canada	Trial registry record	CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1) (CONCOR-1)	McMaster University	ClinicalTrials.gov	16.04.2020	24.02.2021
CONCOR_Canada	Website	COVID-19 and convalescent plasma	Canadian Blood Services	Canadian Blood Services	n.d.	23.09.2020
CONCOR_Canada	Website	Daily COVID-19 digest: April 2, 2020	Canadian Blood Services	Canadian Blood Services	02.04.2020	23.09.2020
CONCOR_Canada	Website	Daily COVID-19 digest: April 30, 2020	Canadian Blood Services	Canadian Blood Services	30.04.2020	23.09.2020
CONCOR_Canada	Website	Daily COVID-19 digest: June 11, 2020	Canadian Blood Services	Canadian Blood Services	11.06.2020	23.09.2020
CONCOR_Canada	Website	Daily COVID-19 digest: May 7, 2020	Canadian Blood Services	Canadian Blood Services	7.05.2020	23.09.2020
CONCOR_Canada	Website	Daily COVID-19 digest: May 14, 2020	Canadian Blood Services	Canadian Blood Services	14.05.2020	23.09.2020
CONCOR_Canada	Website	Daily COVID-19 digest: May 25, 2020	Canadian Blood Services	Canadian Blood Services	25.05.2020	23.09.2020
CONCOR_Canada	Website	Donating Plasma at Canadian Blood Services	Canadian Blood Services	Canadian Blood Services	n.d.	23.09.2020
CONCOR_Canada	Website	First COVID-19 Convalescent Plasma Donor	Canadian Blood Services	Canadian Blood Services	29.04.2020	23.09.2020
CONCOR_Canada	Website	How your plasma donation helps	Canadian Blood Services	Canadian Blood Services	n.d.	23.09.2020
CONCOR_Canada	Website	Open Board Meeting	Canadian Blood Services	Canadian Blood Services	n.d.	23.09.2020
CONCOR_Canada	Website	CONCOR-1 Clinical Trial Website	CONCOR-1	CONCOR-1	n.d.	24.02.2021

The Journal of Law, Medicine & Ethics, 52 (2024): Online: 1-20. © The Author(s), 2024. Published by Cambridge University Press on behalf of American Society of Law, Medicine & Ethics.

Supplementary File 3 (Continued)

Catalogue of sampled documents.

Study Record ID	Document type	Document title	Document author	Document publisher	Date published	Date sampled
CONCOR_Canada	Website	COVID-19 Convalescent Plasma for Patients	Canadian Blood Services	Canadian Blood Services	02.04.2020	27.09.2020
CONCOR_Canada	Website	COVID-19 information for employees and volunteers — filtered Q&A	Canadian Blood Services	Canadian Blood Services	n.d.	23.09.2020
EAP_Mayo_US	Blog	Understanding the FDA's controversial convalescent plasma authorization	Sachs, R	Health Affairs Blog	27.08.2020	14.4.21
EAP_Mayo_US	Blog	Calling all heroes: the power of a plasma partnership	Wood, B	Mitre Corporation	01.10.2020	14.4.21
EAP_Mayo_US	Blog	For early testing of convalescent plasma, we were 'building the plane while we were flying it'	Joyner, M	Stat News	04.03.2021	14.4.21
EAP_Mayo_US	Consent form	Expanded access program patient consent and privacy authorization	Joyner, M	Mayo Clinic	15.04.2020	13.4.21
EAP_Mayo_US	Investigator brochure	Clinical investigator's brochure for use of convalescent plasma to treat Coronavirus-19 (COVID-19) disease V1.0	Joyner, M	Mayo Clinic	04.09.2020	13.4.21
EAP_Mayo_US	News	FDA to allow for plasma therapy for COVID-19 patients	Winter, L	The Scientist	26.04.2020	13.4.21
EAP_Mayo_US	News	A desperate scramble as COVID-19 families vie for access to plasma therapy	Aleccia, J	Kaiser Health News	15.04.2020	13.4.21
EAP_Mayo_US	News	97,000 people got convalescent plasma. Who knows if it worked?	Rogers, A	Wired	21.08.2020	14.4.21
EAP_Mayo_US	News	As Trump praises plasma, researchers struggle to finish critical studies	Thomas, K	The New York Times	04.08.2020	14.4.21
EAP_Mayo_US	News	Market for blood plasma from COVID-19 survivors heats up	Aleccia, J	NPR	11.05.2020	14.4.21
EAP_Mayo_US	News	Two P.R. experts at F.D.A. have been ousted after blood plasma fiasco	Kaplan, S	The New York Times	28.08.2020	14.4.21
EAP_Mayo_US	News	F.D.A. 'grossly misrepresented' blood plasma data, scientists say	Thomas, K	The New York Times	24.08.2020	14.4.21
EAP_Mayo_US	News	F.D.A.'s emergency approval of blood plasma is now on hold	Weiland, N	The New York Times	19.08.2020	14.4.21
EAP_Mayo_US	News	NBA players who've beaten COVID-19 to donate blood for new treatment	Abdelmalek, M	ABC News	31.03.2020	14.4.21
EAP_Mayo_US	News	America needs plasma from COVID-19 survivors now	Zhang, S	The Atlantic	28.03.2020	14.4.21
EAP_Mayo_US	News	Racing against time, medical researchers, life science companies and COVID-19 survivors launch national campaign to drive plasma donation	Harringa, A	Mayo Clinic	26.05.2020	14.4.21

The Journal of Law, Medicine & Ethics, 52 (2024): Online: 1-20.

Supplementary File 3 (Continued)

Catalogue of sampled documents.

Study Record ID	Document type	Document title	Document author	Document publisher	Date published	Date sampled
EAP_Mayo_US	News	Blood plasma from people who recovered is a safe covid-19 treatment, study says	Johnson, CY	The Washington Post	18.06.2020	14.4.21
EAP_Mayo_US	Preprint	Program and patient characteristics for the United States Expanded Access Program to COVID-19 convalescent plasma	Senefeld, J et al (& Joyner, M as SA)	medRxiv	11.04.2021	13.4.21
EAP_Mayo_US	Press release	FDA issues Emergency Use Authorization for convalescent plasma as potential promising COVID–19 treatment, another achievement in administration's fight against pandemic	US FDA	US FDA	23.08.2020	13.4.21
EAP_Mayo_US	Press release	Mayo Clinic receives $26 million from BARDA for COVID-19 convalescent plasma expanded access program	Harringa, A	Mayo Clinic	04.05.2020	13.4.21
EAP_Mayo_US	Press release	Coronavirus (COVID-19) update: FDA coordinates national effort to develop blood-related therapies for COVID-19	US FDA	US FDA	04.03.2020	13.4.21
EAP_Mayo_US	Press release	Mayo Clinic named national site for Convalescent Plasma Expanded Access Program	Anastasijevic, D	Mayo Clinic	04.03.2020	13.4.21
EAP_Mayo_US	Press release	AABB launches new website to inform public about convalescent plasma	AABB	AABB	04.03.2020	14.4.21
EAP_Mayo_US	Press release	Library of Congress selects Mayo's convalescent plasma website for Coronavirus Web Archive	Schanilec, K	Mayo Clinic	19.11.2020	14.4.21
EAP_Mayo_US	Protocol	Expanded access to convalescent plasma for the treatment of patients with COVID-19V 2.0	Joyner, M	Mayo Clinic	03.04.2020	13.4.21
EAP_Mayo_US	Publication	Convalescent plasma antibody levels and the risk of death from Covid-19	Joyner, M et al	The New England Journal of Medicine	13.1.2021	13.4.21
EAP_Mayo_US	Publication	Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients	Joyner, M et al	Proceedings of the Mayo Clinic	19.07.2020	13.4.21
EAP_Mayo_US	Publication	Early safety indicators of COVID-19 convalescent plasma in 5000 patients	Joyner, M et al	J Clin Investigation	11.06.2020	13.4.21
EAP_Mayo_US	Publication	How did we rapidly implement a convalescent plasma program?	Budhai et al	Transfusion	01.07.2020	13.4.21
EAP_Mayo_US	Regulatory	Regulatory documents for sites participating in the National Expanded Access Program (IND 19832) for the use of COVID-19 convalescent plasma in the treatment of COVID-19 disease	Mayo Clinic Institutional Review Board	Mayo Clinic	01.09.2020	13.4.21

The Journal of Law, Medicine & Ethics, 52 (2024): Online: 1-20. © The Author(s), 2024. Published by Cambridge University Press on behalf of American Society of Law, Medicine & Ethics.

Supplementary File 3 (Continued)

Catalogue of sampled documents.

Study Record ID	Document type	Document title	Document author	Document publisher	Date published	Date sampled
EAP_Mayo_US	Regulatory	Emergency Use Authorization request for convalescent plasma for the treatment of patients with COVID-19	Office of the Assistant Secretary for Preparedness and Response	US FDA	23.08.2020	13.4.21
EAP_Mayo_US	Regulatory	Letter in response to request that the Food and Drug Administration (FDA) issue an Emergency Use Authorization (EUA) for emergency use of COVID-19 convalescent plasma	Hinton, DM	US FDA	23.08.2020	13.4.21
EAP_Mayo_US	Regulatory	IRB Continuing Review Approval	Mayo Clinic Institutional Review Board	Mayo Clinic	26.03.2021	13.4.21
EAP_Mayo_US	Regulatory	Comparing EAP vs. EUA:What you need to know	None listed	Mayo Clinic	25.08.2020	13.4.21
EAP_Mayo_US	Regulatory	Investigational COVID-19 convalescent plasma: Guidance for industry	US FDA	US FDA	11.02.2021	13.4.21
EAP_Mayo_US	Regulatory	Letter: EUA high-titer convalescent plasma	US FDA	US FDA	09.03.2021	13.4.21
EAP_Mayo_US	Site list	List of all enrolled sites and providers that were a part of the Expanded Access Program	Joyner, M	Mayo Clinic	04.03.2021	13.4.21
EAP_Mayo_US	Site map	Graphical representation of enrolled patients, blood banks and hospitals by county in the United States	Joyner, M	Mayo Clinic	04.03.2021	13.4.21
EAP_Mayo_US	Trial registry record	Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19	Joyner, M	ClinicalTrials.gov	04.08.2020	14.4.21
EAP_Mayo_US	Website	USCovidPlasma.Org	Joyner, M	Mayo Clinic	2021	13.4.21
EAP_Mayo_US	Website	National COVID-19 Convalescent Plasma Project	CCPP19	Michigan State University	03.03.2021	13.4.21
EAP_Mayo_US	Website	COVIDplasma.org	AABB	AABB	04.03.2020	14.4.21
ITAC_CoVIg-19_Alliance	Blog	Helping survivors become heroes	Bitran, H	Microsoft	20.04.2020	14.4.21
ITAC_CoVIg-19_Alliance	Editorial	Using a global network of adaptive clinical trials to fight Covid-19	Plump, A & Reese, D	Stat News	07.23.2020	24.2.21
ITAC_CoVIg-19_Alliance	News	College says students may have sought COVID-19 infection to boost plasma donor payout	Chappell, B	NPR	13.10.2020	14.4.21
ITAC_CoVIg-19_Alliance	Preprint	Production of anti-SARS-CoV-2 hyperimmune globulin from convalescent plasma	Vandeberg et al.	bioRxiv	20.11.2020	13.4.21

The Journal of Law, Medicine & Ethics, 52 (2024): Online: 1-20.

Supplementary File 3 (Continued)

Catalogue of sampled documents.

Study Record ID	Document type	Document title	Document author	Document publisher	Date published	Date sampled
ITAC_CoVIg-19_Alliance	Preprint	Rapidly increasing SARS-CoV-2 neutralization by intravenous immunoglobulins produced from plasma collected during the 2020 pandemic	Farcet et al (Baxter/Takeda scientists)	bioRxiv	21.02.2021	13.4.21
ITAC_CoVIg-19_Alliance	Press release	Takeda Initiates Development of a Plasma-Derived Therapy for COVID-19	Takeda Pharmaceutical Company Limited	Takeda Pharmaceutical Company Limited	03.04.2020	18.2.21
ITAC_CoVIg-19_Alliance	Press release	Global Plasma Leaders Collaborate to Accelerate Development of Potential COVID-19 Hyperimmune Therapy	Takeda Pharmaceutical Company Limited	Takeda Pharmaceutical Company Limited	04.06.2020	24.2.21
ITAC_CoVIg-19_Alliance	Press release	CoVIg-19 Plasma Alliance Builds Strong Momentum Through Expanded Membership and Clinical Trial Collaboration	Takeda Pharmaceutical Company Limited	Takeda Pharmaceutical Company Limited	05.07.2020	24.2.21
ITAC_CoVIg-19_Alliance	Press release	Racing Against Time, Medical Researchers, Life Science Companies and COVID-19 Survivors Launch National Campaign to Drive Blood Plasma Donation	Takeda Pharmaceutical Company Limited	Takeda Pharmaceutical Company Limited	05.26.2020	24.2.21
ITAC_CoVIg-19_Alliance	Press release	First Patient Enrolled in NIH Phase 3 Trial to Evaluate Potential COVID-19 Hyperimmune Medicine	Takeda Pharmaceutical Company Limited	Takeda Pharmaceutical Company Limited	10.08.2020	24.2.21
ITAC_CoVIg-19_Alliance	Press release	NIH clinical trial testing hyperimmune intravenous immunoglobulin plus remdesivir to treat COVID-19 begins	National Institutes of Health	National Institutes of Health	08.10.2020	12.4.21
ITAC_CoVIg-19_Alliance	Press release	Australian research at the centre of landmark treatment trial for COVID-19	University of New South Wales	University of New South Wales	29.10.2020	12.4.21
ITAC_CoVIg-19_Alliance	Press release	Emergent BioSolutions and Mount Sinai Health System announce initiation of DOD-funded xlinical program to evaluate COVID-19 human hyperimmune globulin (COVID-HIG) product candidate for prophylaxis	Emergent BioSolutions	GlobeNewswire	29.12.2020	13.4.21
ITAC_CoVIg-19_Alliance	Press release	CoVIg-19 Plasma Alliance announces topline results from NIH-sponsored clinical trial of investigational COVID-19 hyperimmune globulin medicine	CoVIg-19 Plasma Alliance	BusinessWire	02.04.2021	12.4.21
ITAC_CoVIg-19_Alliance	Protocol	Protocol Synopsis INSIGHT 013 Inpatient Treatment with Anti-Coronavirus Immunoglobulin	INSIGHT Network	INSIGHT Network	20.08.2020	12.4.21
ITAC_CoVIg-19_Alliance	Report	Grifols 2020 Annual Results	Grifols	Grifols	31.12.2020	13.4.21
ITAC_CoVIg-19_Alliance	Trial registry record	Inpatient Treatment With Anti-Coronavirus Immunoglobulin (ITAC)	University of Minnesota	ClinicalTrials.gov	9.14.2020	24.2.21

The Journal of Law, Medicine & Ethics, 52 (2024): Online: 1-20. © The Author(s), 2024. Published by Cambridge University Press on behalf of American Society of Law, Medicine & Ethics.

Supplementary File 3 (Continued)

Catalogue of sampled documents.

Study Record ID	Document type	Document title	Document author	Document publisher	Date published	Date sampled
ITAC_CoVIg-19_Alliance	Website	Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)	National Institutes of Health	National Institutes of Health	2020	12.4.21
ITAC_CoVIg-19_Alliance	Website	INSIGHT 013 (ITAC)	INSIGHT Network	INSIGHT Network	20.08.2020	12.4.21
ITAC_CoVIg-19_Alliance	Website	CoVIg-19 Plasma Alliance	CoVIg-19 Plasma Alliance	Microsoft	02.24.2021	24.2.21
ITAC_CoVIg-19_Alliance	Website	DonatingPlasma.Org	Plasma Protein Therapeutics Association (PPTA)	Plasma Protein Therapeutics Association (PPTA)	2020	16.3.21
ITAC_CoVIg-19_Alliance	Website	Plasma Protein Therapeutics Association (PPTA)	Plasma Protein Therapeutics Association (PPTA)	Plasma Protein Therapeutics Association (PPTA)	2020	16.3.21
ITAC_CoVIg-19_Alliance	Website	The Fight Is In Us	CoVIg-19 Plasma Alliance	Microsoft and The MITRE Corporation	26.05.2020	16.3.21
ITAC_CoVIg-19_Alliance	Website	Survivor Corps	Survivor Corps	Survivor Corps	16.03.2021	16.3.21
PLACID_India	Blog	The story of the PLACID Tria l— a democratisation of research	Agarwal, A et al	BMJ	02.11.2020	27.11.20
PLACID_India	Editorial	Convalescent plasma is ineffective for covid-19	Pathak, EB	BMJ	23.10.2020	27.11.20
PLACID_India	News	ICMR says no, but here's why doctors are still keen on plasma treatment for Covid patients	Sirur, S & Agarwal, S	The Print	30.10.2020	27.11.20
PLACID_India	News	Plasma therapy under ICMR cloud, Delhi Health Minister bats for it: Saved my life	Saxena, A	The Indian Express	22.10.2020	2.12.20
PLACID_India	News	COVID-19 PLACID trial: ICMR approves 21 institutions for participating in Coronavirus plasma therapy trials	PTI	Financial Express	06.05.2020	3.12.20
PLACID_India	News	Plasma therapy effective for moderately ill patients, say most doctors of IMCR trial	Mehrotra, K	The Indian Express	22.07.2020	3.12.20
PLACID_India	News	How Facebook groups, websites are helping Covid patients connect with plasma donors	Krishnankutty, P	The Print	01.07.2020	3.12.20
PLACID_India	News	COVID-19 In Mumbai: Few Takers For Plasma Therapy	Sarkar, A	Mid-day.com	22.07.2020	3.12.20
PLACID_India	News	Exclusive: Coronavirus pandemic fuels black-market for plasma of recovered patients	Khan, J	India Today	22.07.2020	3.12.20

The Journal of Law, Medicine & Ethics, 52 (2024): Online: 1-20. © The Author(s), 2024. Published by Cambridge University Press on behalf of American Society of Law, Medicine & Ethics.

Supplementary File 3 (Continued)

Catalogue of sampled documents.

Study Record ID	Document type	Document title	Document author	Document publisher	Date published	Date sampled
PLACID_India	News	USFDA may give impetus to plasma therapy in India, experts question efficacy	Mukherjee, R	Times of India	25.08.2020	3.12.20
PLACID_India	Preprint	Convalescent plasma in the management of moderate COVID-19 in India: An open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial)	Agarwal, A et al	MedRx	08.09.2020	2.12.20
PLACID_India	Press release	Evidence Based Advisory to address Inappropriate Use of Convalescent Plasma in COVID-19 Patients	Indian Council of Medical Research	Government of India	17.11.2020	3.12.20
PLACID_India	Protocol	A Phase II, Open Label, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications in Moderate Disease	Drugs Controller General (India)	Government of India	22.04.2020	3.12.20
PLACID_India	Publication	Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)	Agarwal, A et al	BMJ	22.10.2020	27.11.20
PLACID_India	Publication supplement	Supplementary File 1	Agarwal, A et al	BMJ	22.10.2020	27.11.20
PLACID_India	Publication supplement	Annexure 1 Author details (PLACID Trial Collaborators)	Agarwal, A et al	BMJ	22.10.2020	27.11.20
PLACID_India	Regulatory	Information on Convalescent Plasma in COVID-19	Central Drugs Standard Control organisation (Biological Division)	Government of India	01.07.2020	27.11.20
PLACID_India	Regulatory	Permission for approval of protocol for a multi-center two arm prospective, phase-II open labeled randomized controlled trial of convalescent plasma in COVID-19 patients-Regarding	Drugs Controller General (India)	Government of India	14.04.2020	3.12.20
PLACID_India	Study document	Call for Letter of Intent for Participation in: Therapeutic Plasma Exchange in COVID-19: Protocol for a Multi-center, Phase II, Open Label, Randomized Controlled Study	Agarwal, A	Indian Council of Medical Research	12.04.2020	3.12.20
PLACID_India	Study document	Call for Letter of Intent for Participation in: A Phase II, Open Label, Randomized Controlled Study to Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications	Agarwal, A	Indian Council of Medical Research	12.04.2020	3.12.20
PLACID_India	Trial registry record	Study to assess the efficacy and safety of convalescent plasma in moderate COVID-19 disease	Mukherjee, A et al	Clinical Trials Registry of India	21.04.2020	2.12.20

The Journal of Law, Medicine & Ethics, 52 (2024): Online: 1-20. © The Author(s), 2024. Published by Cambridge University Press on behalf of American Society of Law, Medicine & Ethics.

The Journal of Law, Medicine & Ethics, 52 (2024): Online: 1-20. © The Author(s), 2024. Published by Cambridge University Press on behalf of American Society of Law, Medicine & Ethics.

Supplementary File 3 (Continued)

Catalogue of sampled documents.

Study Record ID	Document type	Document title	Document author	Document publisher	Date published	Date sampled
PlasmAr_Argentina	News	Lower house approves bipartisan project to promote blood plasma donation	Buenos Aires Times	Buenos Aires Times	26.06.2020	28.02.21
PlasmAr_Argentina	News	Deputies approved the project that creates a plasma donation campaign	None listed	Télam	26.06.2020	18.02.21
PlasmAr_Argentina	News	Blood Plasma Reduces Risk of Severe Covid-19 if Given Early	Katherine J. Wu	The New York Times	06.01.2021	18.02.21
PlasmAr_Argentina	News	Recovered COVID-19 patients donate plasma for treatment in Argentina	Bianco, ML	Reuters	03.07.2020	24.02.21
PlasmAr_Argentina	News	Argentina - More blood, more life: Argentina's hunt for new donors	None listed	Emerald Group Publishing Limited	04.10.2020	01.03.21
PlasmAr_Argentina	Regulatory	ESPECIALIDAD HEMOTERAPIA	Dirección de Sangre y Hemoderivados	Ministerio de Salud de la Nación	n.d.	01.03.2021
PlasmAr_Argentina	Regulatory	Administrative and Technical Rules (Transfusion regulation)	ESPECIALIDAD HEMOTERAPIA	Ministerio de Salud de la Nación	n.d.	24.02.2021
PlasmAr_Argentina	Website	How We Work: Fundación INFANT	Fundación INFANT	Fundación INFANT	2021	24.02.2021
PlasmAr_Argentina	Website	Proyecto Plasma	Fundación INFANT	Fundación INFANT	n.d.	18.02.2021
PlasmAr_Argentina	Website	Donate Blood In Quarantine	Sarmiento Hematology Foundation	Sarmiento Hematology Foundation	n.d.	20.02.2021
PlasmAr_Argentina	Website	Study results: Plasma of convalescent patients	Fundación INFANT	Fundación INFANT	n.d.	01.03.2021
PlasmAr_Argentina	Website	We are DonARG, and we want to save lives.	DonARG	DonARG	n.d.	18.02.2021
PlasmAr_Argentina	Consent form	Consentimiento informado sobre transfusion de plasma convaleciente de COVID-19 [adult]	Institudo de Hemoterapia	Goberno de la provincia de Buenos Aires	21.09.2020	19.03.2021
PlasmAr_Argentina	Consent form	Consentimiento informado sobre transfusion de plasma convaleciente de COVID-19 [pediatric]	Institudo de Hemoterapia	Goberno de la provincia de Buenos Aires	n.d.	19.03.21
PlasmAr_Argentina	News	Convalescent Plasma Flunks Study in COVID-19 Patients with Severe Pneumonia	Keown, A	BioSpace	25.11.2020	16.03.2021

Supplementary File 3 (Continued)

Catalogue of sampled documents.

Study Record ID	Document type	Document title	Document author	Document publisher	Date published	Date sampled
PlasmAr_Argentina	News	Coronavirus in Argentina: they prepare a large trial with convalescent serum	Bär, N	La Nacion	14.04.2020	17.03.2021
PlasmAr_Argentina	News	No benefit seen from plasma treatment in severe COVID-19; virus may hurt male fertility	Lapid, N	Reuters	25.11.2020	16.03.2021
PlasmAr_Argentina	News	Plasma from recovered patients shows little benefit in those hospitalized with COVID-19: study	Chander,V	Reuters	n.d.	17.03.2021
PlasmAr_Argentina	News	Argentina study moves needle away from convalescent plasma for COVID-19	Wong, S	Biocentury	2021	17.03.2021
PlasmAr_Argentina	News	Plasma extraction for coronavirus: why it is urgent for recovered Argentine patients to donate their blood	Martin, H	Infobae	05.06.2020	17.03.2021
PlasmAr_Argentina	News	COVID-19:This Buenos Aires hospital questions the most famous treatment against the virus	InfoTechnology	InfoTechnology	10.02.2020	18.03.2021
PlasmAr_Argentina	News	Plasma donation: why is it necessary to explain what is important?	Rueda, GD	La Nueva	02.08.2020	20.03.2021
PlasmAr_Argentina	News	The Hospital de Clínicas will use plasma from recovered people as treatment	None listed	Télam	05.05.2020	20.03.2021
PlasmAr_Argentina	Protocol	No effect of Convalescent Plasma in Covid-19 severe pneumonia:The PlasmAr Trial	Simonovich VA, Burgos Pratx LD, Scibona P, et al	The New England Journal of Medicine	2021	10.03.2021
PlasmAr_Argentina	Publication	[Plasma therapy of convalescents in COVID-19 patients in the province of Buenos Aires]	Gonzáles, S et al.	MEDICINA (Buenos Aires)	2020	19.03.2021
PlasmAr_Argentina	Publication	A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia	Simonovich VA, Burgos Pratx LD, et al	The New England Journal of Medicine	18.02.2021	03.03.2021
PlasmAr_Argentina	Publication supplement	Disclosure Forms (blank)	Simonovich VA, Burgos Pratx LD, et al	The New England Journal of Medicine	18.02.2021	10.03.2021
PlasmAr_Argentina	Regulatory	Solicitud de plasma convaleciente COVID-19	Institudo de Hemoterapia	Goberno de la provincia de Buenos Aires	16.06.2020	19.03.2021
PlasmAr_Argentina	Trial registry record	Convalescent Plasma and Placebo for the Treatment of COVID-19 Severe Pneumonia (PLASM-AR)	Hospital Italiano de Buenos Aires	ClinicalTrials.gov	05.12.2020	18.03.2021
PlasmAr_Argentina	Website	Convalescent Plasma and Placebo for the Treatment of COVID-19 Severe Pneumonia (PLASM-AR)	ClinicalTrials.gov	ClinicalTrials.gov	12.05.2020	16.03.2021

The Journal of Law, Medicine & Ethics, 52 (2024): Online: 1-20. © The Author(s), 2024. Published by Cambridge University Press on behalf of American Society of Law, Medicine & Ethics.

Supplementary File 3 (Continued)

Catalogue of sampled documents.

Study Record ID	Document type	Document title	Document author	Document publisher	Date published	Date sampled
PlasmAr_Argentina	Website	Scientists develop protocols to use the plasma from recovered patients in the treatment of severe cases of COVID-19	Biological and Health Sciences	Conicet	17.04.2020	18.03.2021
PlasmAr_Argentina	Website	A group of scientists and doctors, who ad honorem, are developing emergency protocols for the use of plasma from convalescent patients COVID-19 to patients who have the disease	CPC-19	CPC-19	2020	20.03.2021
PlasmAr_Argentina	Website	Plasma donation from recovered COVID-19 patients	Argentina Unida	Argentina Unida	n.d.	19.03.2021
PlasmAr_Argentina	Website	La Plata,15 de Septiembre de 2020	Goberno de la provincia de Buenos Aires	Goberno de la provincia de Buenos Aires	15.09.2020	19.03.2021
PlasmAr_Argentina	Website	Resultados del ensayo PLASM-AR	Hospital Italiano	Hospital Italiano	n.d.	19.03.2021
PlasmAr_Argentina	Website	Resultados del ensayo PLASM-AR	Hospital Italiano	Hospital Italiano	n.d.	19.03.2021
PlasmAr_Argentina	Website	A promising COVID-19 treatment gets fast-tracked	Spencer, G	Johns Hopkins University	08.04.2020	18.03.2021
PlasmAr_Argentina	Website	Health Regulations in the Health Emergency Declared for COVID-19	Mairal, MO	Mairal, MO	15.10.2020	18.03.2021
RECOVERY_UK	Blog	Support of NHS staff will be crucial in testing convalescent plasma treatment for the sickest COVID-19 patients	Miflin, G	NHS England	25.06.2020	11.12.20
RECOVERY_UK	Blog	How we're supporting COVID-19 convalescent plasma trials	Pinches, H	NHS Digital	30.06.2020	11.12.20
RECOVERY_UK	COI disclosure forms	Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report	The RECOVERY Collaborative Group	The New England Journal of Medicine	17.07.2020	10.12.20
RECOVERY_UK	Consent form	Participant Information and Consent Form (Adults)	The RECOVERY Collaborative Group	University of Oxford	21.11.2020	10.12.20
RECOVERY_UK	Consent form	Participant Information and Consent Form (Children)	The RECOVERY Collaborative Group	University of Oxford	26.10.2020	10.12.20
RECOVERY_UK	Data sharing statement	Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report	The RECOVERY Collaborative Group	The New England Journal of Medicine	17.07.2020	10.12.20

The Journal of Law, Medicine & Ethics, 52 (2024): Online: 1-20.

Supplementary File 3 (Continued)

Catalogue of sampled documents.

Study Record ID	Document type	Document title	Document author	Document publisher	Date published	Date sampled
RECOVERY_UK	Editorial	The RECOVERY Platform	Normand, SL	The New England Journal of Medicine	21.07.2020	11.12.20
RECOVERY_UK	Letter	The importance of increasing recruitment	Chief Medical Officers of Health	National Health Service	18.08.2020	10.12.20
RECOVERY_UK	Letter	The importance of COVID-19 clinical trials	Chief Medical Officers of Health	National Health Service	01.04.2020	10.12.20
RECOVERY_UK	Letter	Recruiting patients for clinical trials for Covid-19 therapeutics	Chief Medical Officers of Health	National Health Service	06.05.2020	10.12.20
RECOVERY_UK	Letter	Request for support: Randomised evaluation of COVID-19 therapy (RECOVERY trial)	Department of Health & Social Care, NIHR	National Health Service	16.03.2020	10.12.20
RECOVERY_UK	Letter	Letter from Data Monitoring Committee December 3 2020	Data Monitoring Committee Chairman	University of Edinburgh	03.12.2020	10.12.20
RECOVERY_UK	Minutes	200227_NERVTAG therapeutics sub committee minute_FINAL	NERVTAG	Government of the United Kingdom	27.02.2020	11.11.21
RECOVERY_UK	Minutes	NERVTAG_Member_Bios_update_July2021	NERVTAG	Government of the United Kingdom	07.01.2021	11.11.21
RECOVERY_UK	Minutes	200302_NERVTAG therapeutics subgroup Minutes_FINAL	NERVTAG	Government of the United Kingdom	03.02.2020	11.11.21
RECOVERY_UK	Minutes	200309_NERVTAG therapeutics subcommittee Minutes _FINAL	NERVTAG	Government of the United Kingdom	03.09.2020	11.11.21
RECOVERY_UK	Minutes	RECOVERY collaborators' meeting 7th & 8th December	The RECOVERY Collaborative Group	University of Oxford	08.12.2020	10.12.20
RECOVERY_UK	News	RECOVERY trial: the UK covid-19 study resetting expectations for clinical trials	Wilkinson, E	BMJ	28.04.2020	10.12.20
RECOVERY_UK	News	Coronavirus: world's biggest trial of drug to treat Covid-19 begins in UK	Boseley, S	The Guardian	17.04.2020	10.12.20
RECOVERY_UK	News	Covid-19: The inside story of the RECOVERY trial	Wise, J & Coombes, R	BMJ	08.07.2020	10.12.20
RECOVERY_UK	News	One U.K. trial is transforming COVID-19 treatment. Why haven't others delivered more results?	Kupferschmidt, K	Science	02.07.2020	11.12.20

The Journal of Law, Medicine & Ethics, 52 (2024): Online: 1-20. © The Author(s), 2024. Published by Cambridge University Press on behalf of American Society of Law, Medicine & Ethics.

Supplementary File 3 (Continued)

Catalogue of sampled documents.

Study Record ID	Document type	Document title	Document author	Document publisher	Date published	Date sampled
RECOVERY_UK	News	Pressure grows on UK to routinely treat Covid-19 patients with the blood of survivors after US grants it emergency approval — but scientists warn there is still no proof it works	Chalmers,V	The Daily Mail	24.08.2020	11.12.20
RECOVERY_UK	News	Covid-19: NHS hospitals are urged to recruit more patients to Recovery trial to find what treatments work	Iacobucci, G	BMJ	05.11.2020	11.12.20
RECOVERY_UK	News	First person to donate plasma after receiving plasma for COVID	NHS	NHS Blood and Transplant	05.11.2020	11.12.20
RECOVERY_UK	Poster	Have you been admitted to hospital with suspected or confirmed COVID-19?	The RECOVERY Collaborative Group	University of Oxford	11.06.2020	10.12.20
RECOVERY_UK	Poster	Are you looking after a patient with COVID-19? Have they been admitted?	The RECOVERY Collaborative Group	University of Oxford	14.04.2020	10.12.20
RECOVERY_UK	Poster	Quick guide to receiving conset	The RECOVERY Collaborative Group	University of Oxford	08.07.2020	10.12.20
RECOVERY_UK	Poster	Quick guide to follow up	The RECOVERY Collaborative Group	University of Oxford	02.04.2020	10.12.20
RECOVERY_UK	Preprint	Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial	The RECOVERY Collaborative Group	medRxiv	10.03.2021	13.4.21
RECOVERY_UK	Press release	RECOVERY trial closes recruitment to convalescent plasma treatment for patients hospitalised with COVID-19	The RECOVERY Collaborative Group	Nuffield Department of Population Health	15.01.2021	11.12.21
RECOVERY_UK	Protocol	Randomised Evaluation of COVID-19 Therapy (RECOVERY)	The RECOVERY Collaborative Group	University of Oxford	11.21.2020	10.12.20
RECOVERY_UK	Protocol	Supplementary Appendix: Protocol and statistical analysis plan	The RECOVERY Collaborative Group	The New England Journal of Medicine	17.07.2020	10.12.20
RECOVERY_UK	Publication	Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report	The RECOVERY Collaborative Group	The New England Journal of Medicine	17.07.2020	10.12.20

The Journal of Law, Medicine & Ethics, 52 (2024): Online: 1-20.

Supplementary File 3 (Continued)

Catalogue of sampled documents.

Study Record ID	Document type	Document title	Document author	Document publisher	Date published	Date sampled
RECOVERY_UK	Publication	Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial	The RECOVERY Collaborative Group	The Lancet	05.10.2020	10.12.20
RECOVERY_UK	Publication	Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19	The RECOVERY Collaborative Group	The New England Journal of Medicine	19.11.2020	10.12.20
RECOVERY_UK	Publication supplement	Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report	The RECOVERY Collaborative Group	The New England Journal of Medicine	17.7.2020	10.12.20
RECOVERY_UK	Study document	Sample randomisation form — convalescent plasma and monoclonal antibody	The RECOVERY Collaborative Group	University of Oxford	25.11.2020	10.12.20
RECOVERY_UK	Training material	RECOVERY intervention sheet — assessing patients for risk of transfusion associated circulatory overload (TACO) prior to convalescent plasma transfusions	The RECOVERY Collaborative Group	University of Oxford	n.d.	10.12.20
RECOVERY_UK	Training material	Convalescent plasma training powerpoint	The RECOVERY Collaborative Group	University of Oxford	11.707.2020	10.12.20
RECOVERY_UK	Trial registry record	Randomised Evaluation of COVID-19 Therapy (RECOVERY)	University of Oxford	EU Clinical Trials Register	19.03.2020	10.12.20
RECOVERY_UK	Trial registry record	Randomised Evaluation of COVID-19 Therapy (RECOVERY)	University of Oxford	ClinicalTrials.gov	11.05.2020	10.12.20
RECOVERY_UK	Trial registry record	A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus)	University of Oxford	ISRCTN Registry	30.03.2020	10.12.20
RECOVERY_UK	Website	RECOVERY: Randomised Evaluation of COVID-19 Therapy	Nuffield Department of Population Health	University of Oxford	n.d.	10.12.20
RECOVERY_UK	Website	For patients	The RECOVERY Collaborative Group	University of Oxford	10.12.2020	10.12.20
REMAP CAP_UK	Letter	Novel Coronavirus: Clinical Trials	Chief Medical Officers of Health UK	National Health Service	2020	18.01.22

The Journal of Law, Medicine & Ethics, 52 (2024): Online: 1-20. © The Author(s), 2024. Published by Cambridge University Press on behalf of American Society of Law, Medicine & Ethics.

Supplementary File 3 (Continued)

Catalogue of sampled documents.

Study Record ID	Document type	Document title	Document author	Document publisher	Date published	Date sampled
REMAP CAP_UK	Letter	Recruiting patients for clinical trials for COVID-19 therapeutics	Chief Medical Officers of Health UK	National Health Service	06.05.2020	27.01.21
REMAP CAP_UK	News	COVID-19: NHS urges patients who beat coronavirus to keep donating blood plasma despite new findings	Moore, T	Sky News	11.01.2021	25.01.21
REMAP CAP_UK	News	Expert reaction to REMAP-CAP recruitment of severely ill COVID-19 patients into convalescent plasma trial being paused after initial analysis suggested it did not improve outcomes	Science Media Centre	Science Media Centre	11.01.2021	03.02.21
REMAP CAP_UK	Press release	Oxford University Press Release: Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19	The RECOVERY Collaborative Group	Oxford University	16.06.2020	27.01.21
REMAP CAP_UK	Protocol	Randomized, Embedded, Multifactorial Adaptive Platform trial for Community Acquired Pneumonia (REMAP-CAP): CORE PROTOCOL	REMAP-CAP	REMAP-CAP	10.07.2019	25.01.21
REMAP CAP_UK	Protocol	COVID-19 Immunoglobulin Therapy Domain□ Specific Appendix Version 2.4.2 dated 23 July 2020	REMAP-CAP	REMAP-CAP	23.07.2020	03.02.21
REMAP CAP_UK	Protocol	COVID-19 Immunoglobulin Therapy Domain-Specific Appendix Version 1.01 dated 01 June 2020	REMAP-CAP	REMAP-CAP	01.06.2020	03.02.21
REMAP CAP_UK	Publication	Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19 The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial	The Writing Committee for the REMAP-CAP Investigators	JAMA	6.10.2020	27.01.21
REMAP CAP_UK	Publication	Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis	Mehra MR, Desai SS, Ruschitzka F, Patel, AM	The Lancet	22.05.2020	27.01.21
REMAP CAP_UK	Publication	A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19	Cao B, Wang Y, Wen D, et al	The New England Journal of Medicine	07.05.2020	27.01.21
REMAP CAP_UK	Publication	Retraction — Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis	Mandeep R M, Ruschitzka F, Patel A M	The Lancet	04.06.2021	27.01.21
REMAP CAP_UK	Publication supplement	Data Sharing Statement	The Writing Committee for the REMAP-CAP Investigators	JAMA	6.10.2020	03.02.21

The Journal of Law, Medicine & Ethics, 52 (2024): Online: 1-20.

Supplementary File 3 (Continued)

Catalogue of sampled documents.

Study Record ID	Document type	Document title	Document author	Document publisher	Date published	Date sampled
REMAP CAP_UK	Social media	Important Results coming out of #convalescent plasma	Miflin, G	Twitter	11.01.2021	25.01.21
REMAP CAP_UK	Trial registry record	Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (REMAP-CAP)	Derde, L, UMC Utrecht	ClinicalTrials.gov	04.13.2016	18.01.21
REMAP CAP_UK	Trial registry record	An international platform trial for severely ill patients with community-acquired pneumonia or COVID-19	Albeidh, F	ISRCTN Registry	20.7.2020	18.01.21
REMAP CAP_UK	Trial registry record	Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP). (COVID-19)	REMAP-CAP	EU Clinical Trials Register	09.16.2015	
REMAP CAP_UK	Website	Community-Acquired Pnemonia	REMAP-CAP	REMAP-CAP	n.d.	18.01.21
REMAP CAP_UK	Website	COVID-19 Publications	REMAP-CAP	REMAP-CAP	n.d.	25.01.21
REMAP CAP_UK	Website	Pandemic Preparedness	REMAP-CAP	REMAP-CAP	2020	18.01.21
REMAP CAP_UK	Website	Participating Sites	REMAP-CAP	REMAP-CAP	2020	18.01.21
REMAP CAP_UK	Website	5. PRACTICE C: RANDOMIZED, EMBEDDED, MULTIFACTORIAL,ADAPTIVE PLATFORM TRIAL SEVERE CAP –WORKPACKAGE 5	PREPARE EUROPE	PREPARE EUROPE	n.d.	28.01.21
REMAP CAP_UK	Website	Study Detail: Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia	National Institute for Health Research	National Institute for Health Research	15.01.2021	18.01.21
REMAP CAP_UK	Website	REMAP-CAP: Corticosteroids in COVID-19	Walker, G	The Bottom Line	11.09.2020	03.02.21
REMAP CAP_UK	Website	REMAP-CAP response to the COVID-19 pandemic	REMAP-CAP	REMAP-CAP	n.d.	18.01.21
REMAP CAP_UK	Website	Who can donate plasma?	NHS Blood and Transplant	NHS Blood and Transplant	n.d.	03.02.21
REMAP CAP_UK	Website	What is an adaptive clinical trial?	REMAP-CAP	REMAP-CAP	n.d.	18.01.21

The Journal of Law, Medicine & Ethics, 52 (2024): Online: 1-20. © The Author(s), 2024. Published by Cambridge University Press on behalf of American Society of Law, Medicine & Ethics.